Vertebral compression fractures in multiple myeloma: Part II. Assessment of fracture risk with MR imaging of spinal bone marrow

Radiology

Volumn 204, Issue 1, 1997, Pages 201-205

  Lecouvet, Frédéric E ^a   Malghem, Jacques ^a   Michaux, Lucienne ^a   Michaux, Jean Louis ^a   Lehmann, Frédéric ^a   Maldague, Baudouin E ^a   Jamart, Jacques ^b   Ferrant, Augustin ^a   Vande Berg, Bruno C ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

Author keywords

Bone marrow, abnormalities; Gadolinium; Myeloma; Osteoporosis; Spine, fractures; Spine, MR

Indexed keywords

ADULT; AGED; ARTICLE; BONE MARROW; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL; THORACOLUMBAR SPINE; VERTEBRA FRACTURE;

EID: 0030990087     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.204.1.9205247     Document Type: Article

References (30)

1. Salmon SE, Cassady JR. Plasma cell neoplasms. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 4th ed. Philadelphia, Pa: Lippincott, 1993; 1984-2025.
2. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975; 50:29-40.
3. Spiess JL, Adelstein DJ, Mines JD. Multiple myeloma presenting with spinal cord compression. Oncology 1988; 45:88-92.
4. Weinstein RS. Bone involvement in multiple myeloma. Am J Med 1992; 93:591-594.
5. Heiser S, Schwartzman JJ. Variations in the roentgen appearance of the skeletal system in myeloma. Radiology 1952; 58:178-191.
6. Riccardi A, Gobbi PG, Ucci G, et al. Changing clinical presentation of multiple myeloma. Eur J Cancer 1991; 27:1401-1405.
7. Kapadia SB. Multiple myeloma: a clinicopathologic study of 62 consecutively autopsied cases. Medicine 1980; 59:380-392.
8. Kanis JA, Mc Closkey EV. Disorders of calcium metabolism and their management. In: Malpas JS, Bergsagel DE, Kyle RA, eds. Myeloma: biology and management. New York, NY: Oxford University Press, 1995; 375-396.
9. Bataille R. Management of myeloma with bisphosphonates. N Engl J Med 1996; 334: 529-530.
10. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334: 488-493.
11. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992; 340:1049-1052.
12. Belch AR, Bergsagel DE, Wilson K, et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991; 9:1397-1402.
13. Clemens MR, Fessele K, Heim ME. Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications. Ann Haematol 1993; 66:141-146.
14. Delmas PD. The use of clodronate in multiple myeloma. Bone 1991; 12:531-534.
15. Laakso M, Lahtinen R, Virkkunen P, Elomaa I. Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Br J Haematol 1994; 87:725-729.
16. Ludwig H, Tscholakoff D, Neuhold A, Frühwald F, Rasoul S, Fritz E. Magnetic resonance imaging of the spine in multiple myeloma. Lancet 1987; 15:364-366.
17. Moulopoulos LA, Varma DGK, Dimopoulos MA, et al. Multiple myeloma: spinal MR imaging in patients with untreated newly diagnosed disease. Radiology 1992; 185:833-840.
18. Moulopoulos LA, Dimopoulos MA, Alexanian R, Leeds NE, Libshitz HI. Multiple myeloma: MR patterns of response to treatment. Radiology 1994; 193:441-446.
19. Carlson K, Aström G, Nyman R, Ahlström H, Simonsson B. MR imaging of multiple myeloma in tumour mass measurement at diagnosis and during treatment. Acta Radiol 1995; 36:9-14.
20. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36:842-854.
21. Lecouvet FE, Vande Berg BC, Maldague BE, et al. Vertebral compression fractures in multiple myeloma. I. Distribution and appearance at MR imaging. Radiology 1997; 204:195-199.
22. Vande Berg BC, Lecouvet FE, Michaux L, et al. Stage I multiple myeloma: value of MR imaging of the bone marrow in the determination of prognosis. Radiology 1996; 201: 243-246.
23. Wolfe RA, Strawderman RL. Logical and statistical fallacies in the use of Cox regression models. Am J Kidney Dis 1996; 27:124-129.
24. Joffe J, Williams MP, Cherryman GR, Gore M, McElwain TJ, Selby P. Magnetic resonance imaging in myeloma (letter). Lancet 1988; 1:1162-1163.
25. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Arch Intern Med 1990; 112:352-364.
26. Taube T, Beneton MNC, McCloskey EV, Rogers S, Greaves M, Kanis JA. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 1992; 49: 192-198.
27. Durie BGM, Salmon SE, Mundy GR. Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma. Br J Haematol 1981; 47:21-30.
28. Bataille R, Chappard D, Alexandre C, Dessauw P, Sany J. Importance of quantitative histology of bone changes in monoclonal gammopathy. Br J Cancer 1986; 53:805-810.
29. Bataille R, Delmas PD, Chappard D, Sany J. Abnormal serum bone Gla protein levels in multiple myeloma: crucial role of bone formation and prognostic implications. Cancer 1990; 66:167-172.
30. Mariette X, Khalifa P, Ravaud P, et al. Bone densitometry in patients with multiple myeloma. Am J Med 1992; 93:595-598.